About neuro bioscience - NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
NRBO At a Glance
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue
Cambridge, Massachusetts 02138
| Phone | 1-857-702-9600 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -12,470,000.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
NRBO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.087 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.22 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.058 |
NRBO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,558,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NRBO Liquidity
| Current Ratio | 3.777 |
| Quick Ratio | 3.777 |
| Cash Ratio | 3.764 |
NRBO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -44.287 |
| Return on Equity | -64.889 |
| Return on Total Capital | -73.839 |
| Return on Invested Capital | -64.66 |
NRBO Capital Structure
| Total Debt to Total Equity | 1.217 |
| Total Debt to Total Capital | 1.202 |
| Total Debt to Total Assets | 0.891 |
| Long-Term Debt to Equity | 0.815 |
| Long-Term Debt to Total Capital | 0.805 |